Universitätsklinik für Psychiatrie und Psychotherapie Bielefeld
- Address
- Remterweg 69/71, 33617 Bielefeld, Germany
Universitätsklinik für Psychiatrie und Psychotherapie Bielefeld - Treatment-Resistant Psychiatric Disorders Center
The Universitätsklinik für Psychiatrie und Psychotherapie Bielefeld is a leading psychiatric research institution specializing in innovative treatment approaches for patients experiencing first-line treatment failure. The center focuses on developing and evaluating early-intensified pharmacological interventions for major psychiatric disorders, comparing these novel strategies against standard treatment as usual protocols to optimize patient outcomes.
- Treatment-resistant schizophrenia, schizoaffective disorder, and schizophreniform disorder with PANSS-based outcome measures
- Major depressive disorder and bipolar depression utilizing Montgomery Åsberg Depression Rating Scale (MADRS) assessments
- Comparative effectiveness research of intensified versus standard pharmacological treatment protocols
The center's research program systematically addresses the critical challenge of treatment non-response across multiple psychiatric conditions through rigorous randomized controlled trials. By investigating early treatment intensification strategies following initial treatment failure, the clinic aims to establish evidence-based protocols that can significantly improve symptom reduction and functional recovery for patients with severe mental illness who do not respond adequately to first-line interventions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 1 therapeutic areas and 15 of 52 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 48 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Universitätsklinik für Psychiatrie und Psychotherapie Bielefeld
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A randomised, controlled trial to investigate the effect of a four/six week intensified pharmacological treatment for schizophrenia, major depressive disorder and bipolar depression compared to treatment as usual in subjects who had a first-time treatment failure on their first-line treatment. | Universitair Medisch Centrum Utrecht | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 52 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bupropion Hydrochloride | 3 | Unknown | 2024-08-29 | 2025-02-11 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.